Skip to main content
. 2024 Aug 8;73(4):1–126. doi: 10.15585/mmwr.rr7304a1

TABLE. K1. Summary of classifications for hormonal contraceptive methods and intrauterine devices.

Condition Cu-IUD
 LNG-IUD
 Implant
 DMPA
 POP
 CHC
Personal Characteristics and Reproductive History
Pregnancy
4*
 4*
 NA*
 NA*
 NA*
 NA*
Age
Menarche to 
<20 years: 2
 Menarche to 
<20 years: 2
 Menarche to 
<18 years: 1
 Menarche to 
<18 years: 2
 Menarche to 
<18 years: 1
 Menarche to 
<40 years: 1
≥20 years: 1
 ≥20 years: 1
 18–45 years: 1
 18–45 years: 1
 18–45 years: 1
 ≥40 years: 2
>45 years: 1
 >45 years: 2
 >45 years: 1
Parity
a. Nulliparous
 2
 2
 1
 1
 1
 1
b. Parous
 1
 1
 1
 1
 1
 1
Breastfeeding
a. <21 days postpartum
 —
 —
 2*
 2*
 2*
 4*
b. 21 to <30 days postpartum
  i. With other risk factors for VTE (e.g., age ≥35 years, previous VTE, thrombophilia, immobility, transfusion at delivery, peripartum cardiomyopathy, BMI ≥30 kg/m2, postpartum hemorrhage, postcesarean delivery, preeclampsia, or smoking)
 —
 —
 2*
 2*
 2*
 3*
  ii. Without other risk factors for VTE
 —
 —
 2*
 2*
 2*
 3*
c. 30–42 days postpartum
  i. With other risk factors for VTE (e.g., age ≥35 years, previous VTE, thrombophilia, immobility, transfusion at delivery, peripartum cardiomyopathy, BMI ≥30 kg/m2, postpartum hemorrhage, postcesarean delivery, preeclampsia, or smoking)
 —
 —
 1*
 2*
 1*
 3*
  ii. Without other risk factors for VTE
 —
 —
 1*
 1*
 1*
 2*
d. >42 days postpartum
 —
 —
 1*
 1*
 1*
 2*
Postpartum (nonbreastfeeding)
a. <21 days postpartum
 —
 —
 1
 2
 1
 4
b. 21–42 days postpartum
  i. With other risk factors for VTE (e.g., age ≥35 years, previous VTE, thrombophilia, immobility, transfusion at delivery, peripartum cardiomyopathy, BMI ≥30 kg/m2, postpartum hemorrhage, postcesarean delivery, preeclampsia, or smoking)
 —
 —
 1
 2
 1
 3*
  ii. Without other risk factors for VTE
 —
 —
 1
 1
 1
 2
c. >42 days postpartum
 —
 —
 1
 1
 1
 1
Postpartum (including cesarean delivery, breastfeeding,
or nonbreastfeeding)
a. <10 minutes after delivery of the placenta
 2*
 2*
 —
 —
 —
 —
b. 10 minutes after delivery of the placenta to <4 weeks
 2*
 2*
 —
 —
 —
 —
c. ≥4 weeks
 1*
 1*
 —
 —
 —
 —
d. Postpartum sepsis
 4
 4
 —
 —
 —
 —
Postabortion (spontaneous or induced)
a. First trimester abortion
  i. Procedural (surgical)
 1*
 1*
 1*
 1*
 1*
 1*
  ii. Medication
 1*
 1*
 1*
 1/2*
 1*
 1*
  iii. Spontaneous abortion with no intervention
 1*
 1*
 1*
 1*
 1*
 1*
b. Second trimester abortion
  i. Procedural (surgical)
 2*
 2*
 1*
 1*
 1*
 1*
  ii. Medication
 2*
 2*
 1*
 1*
 1*
 1*
  iii. Spontaneous abortion with no intervention
 2*
 2*
 1*
 1*
 1*
 1*
c. Immediate postseptic abortion
 4
 4
 1*
 1*
 1*
 1*
Past ectopic pregnancy
1
 1
 1
 1
 2
 1
History of pelvic surgery (see recommendations for Postpartum [including cesarean delivery])
 1
 1
 1
 1
 1
 1
Smoking
a. Age <35 years
 1
 1
 1
 1
 1
 2
b. Age ≥35 years
  i. <15 cigarettes per day
 1
 1
 1
 1
 1
 3
  ii. ≥15 cigarettes per day
 1
 1
 1
 1
 1
 4
Obesity
a. BMI ≥30 kg/m2
 1
 1
 1
 1
 1
 2*
b. Menarche to <18 years and BMI ≥30 kg/m2
 1
 1
 1
 2
 1
 2*
History of bariatric surgery
This condition is associated with increased risk for
adverse health events as a result of pregnancy (Box 3).
a. Restrictive procedures: decrease storage capacity of the stomach (vertical banded gastroplasty, laparoscopic adjustable gastric band, or laparoscopic sleeve gastrectomy)
 1
 1
 1
 1
 1
 1
b. Malabsorptive procedures: decrease absorption of nutrients and calories by shortening the functional length of the small intestine (Roux-en-Y gastric bypass or biliopancreatic diversion)
 1
 1
 1
 1
 3
 COCs: 3
Patch and ring: 1
Surgery
a. Minor surgery without immobilization
 1
 1
 1
 1
 1
 1
b. Major surgery
  i. Without prolonged immobilization
 1
 1
 1
 1
 1
 2
  ii. With prolonged immobilization
 1
 1
 1
 2
 1
 4
Cardiovascular Disease
Multiple risk factors for atherosclerotic cardiovascular disease (e.g., older age, smoking, diabetes, hypertension, low HDL, high LDL, or high triglyceride levels)
 1
 2
 2*
 3*
 2*
 3/4*
Hypertension
Systolic blood pressure ≥160 mm Hg or diastolic blood
pressure ≥100 mm Hg are associated with increased
risk for adverse health events as a result
of pregnancy (Box 3).
a. Adequately controlled hypertension
 1*
 1*
 1*
 2*
 1*
 3*
b. Elevated blood pressure levels (properly taken
measurements)
  i. Systolic 140–159 mm Hg or diastolic 90–99 mm Hg
 1*
 1*
 1*
 2*
 1*
 3*
  ii. Systolic ≥160 mm Hg or diastolic ≥100 mm Hg
 1*
 2*
 2*
 3*
 2*
 4*
c. Vascular disease
 1*
 2*
 2*
 3*
 2*
 4*
History of high blood pressure during pregnancy (when current blood pressure is measurable and normal)
 1
 1
 1
 1
 1
 2
Deep venous thrombosis/Pulmonary embolism
This condition is associated with increased risk
for adverse health events as a result of
pregnancy (Box 3).
a. Current or history of DVT/PE, receiving anticoagulant therapy (therapeutic dose) (e.g., acute DVT/PE or long-term therapeutic dose)
 2*
 2*
 2*
 2*
 2*
 3*
b. History of DVT/PE, receiving anticoagulant therapy
(prophylactic dose)
  i. Higher risk for recurrent DVT/PE (one or more risk factors)
 2*
 2*
 2*
 3*
 2*
 4*
     • Thrombophilia (e.g., factor V Leiden mutation; prothrombin gene mutation; protein S, protein C, and antithrombin deficiencies; or antiphospholipid syndrome)
     • Active cancer (metastatic, receiving therapy, or within 6 months after clinical remission), excluding nonmelanoma skin cancer
     • History of recurrent DVT/PE
  ii. Lower risk for recurrent DVT/PE (no risk factors)
 2*
 2*
 2*
 2*
 2*
 3*
c. History of DVT/PE, not receiving anticoagulant therapy
  i. Higher risk for recurrent DVT/PE (one or more risk factors
 1
 2
 2
 3
 2
 4
     • History of estrogen-associated DVT/PE
     • Pregnancy-associated DVT/PE
     • Idiopathic DVT/PE
     • Thrombophilia (e.g., factor V Leiden mutation; prothrombin gene mutation; protein S, protein C, and antithrombin deficiencies; or antiphospholipid syndrome)
     • Active cancer (metastatic,
     receiving therapy, or within 6 months after clinical remission), excluding nonmelanoma skin
     cancer
     • History of recurrent DVT/PE
  ii. Lower risk for recurrent DVT/PE (no risk factors)
 1
 2
 2
 2
 2
 3
d. Family history (first-degree relatives)
 1
 1
 1
 1
 1
 2
Thrombophilia (e.g., factor V Leiden mutation; prothrombin gene mutation; protein S, protein C, and antithrombin deficiencies; or antiphospholipid syndrome)
This condition is associated with increased risk for adverse health events as a result of pregnancy (Box 3).
 1*
 2*
 2*
 3*
 2*
 4*
Superficial venous disorders
a. Varicose veins
 1
 1
 1
 1
 1
 1
b. Superficial venous thrombosis (acute or history)
 1
 1
 1
 2
 1
 3*
Current and history of ischemic heart disease
This condition is associated with increased risk for adverse health events as a result of pregnancy (Box 3).
 1
 Initiation
 Continuation
 Initiation
 Continuation
 3
 Initiation
 Continuation
 4
2
 3
 2
 3
 2
 3
Stroke (history of cerebrovascular accident)
This condition is associated with increased risk for adverse health events as a result of pregnancy (Box 3).
 1
 2
 Initiation
 Continuation
 3
 Initiation
 Continuation
 4
2
 3
 2
 3
Valvular heart disease
Complicated valvular heart disease is associated with
increased risk for adverse health events as a result of
pregnancy (Box 3).
a. Uncomplicated
 1
 1
 1
 1
 1
 2
b. Complicated (pulmonary hypertension, risk for atrial fibrillation, or history of subacute bacterial endocarditis)
 1
 1
 1
 2
 1
 4
Peripartum cardiomyopathy
This condition is associated with increased risk for
adverse health events as a result of pregnancy (Box 3).
a. Normal or mildly impaired cardiac function (New 
York Heart Association Functional Class I or II: no
limitation of activities or slight, mild limitation
of activity) (3)
  i. <6 months
 2
 2
 1
 2
 1
 4
  ii. ≥6 months
 2
 2
 1
 2
 1
 3
b. Moderately or severely impaired cardiac function (New York Heart Association Functional Class III or IV: marked limitation of activity or should be at complete rest) (3)
 2
 2
 2
 3
 2
 4
Renal Disease
Chronic kidney disease
This condition is associated with increased risk
for adverse health events as a result of pregnancy (Box 3).
 Initiation
 Continuation
 Initiation
 Continuation
 —
a. Current nephrotic syndrome
 1
 1
 2
 2
 2
 3
 2*
DRSP POP with known hyperkalemia: 4*
 4
b. Hemodialysis
 1
 1
 2
 2
 2
 3
 2*
DRSP POP with known hyperkalemia: 4*
 4
c. Peritoneal dialysis
 2
 1
 2
 2
 2
 3
 2*
DRSP POP with known hyperkalemia: 4*
 4
Rheumatic Diseases
Systemic lupus erythematosus
This condition is associated with increased risk for adverse health events as a result of pregnancy (Box 3).
 Initiation
 Continuation
 —
 Initiation
 Continuation
 —
a. Positive (or unknown) antiphospholipid antibodies
 1*
 1*
 2*
 2*
 3*
 3*
 2*
 4*
b. Severe thrombocytopenia
 3*
 2*
 2*
 2*
 3*
 2*
 2*
 2*
c. Immunosuppressive therapy
 2*
 1*
 2*
 2*
 2*
 2*
 2*
 2*
d. None of the above
 1*
 1*
 2*
 2*
 2*
 2*
 2*
 2*
Rheumatoid arthritis
Initiation
 Continuation
 Initiation
 Continuation
 —
a. Not receiving immunosuppressive therapy
 1
 1
 1
 1
 1
 2
 1
 2
b. Receiving immunosuppressive therapy
 2
 1
 2
 1
 1
 2/3*
 1
 2
Neurologic Conditions
Headaches
a. Nonmigraine (mild or severe)
 1
 1
 1
 1
 1
 1*
b. Migraine
  i. Without aura (includes menstrual migraine)
 1
 1
 1
 1
 1
 2*
  ii. With aura
 1
 1
 1
 1
 1
 4*
Epilepsy
This condition is associated with increased risk for adverse health events as a result of pregnancy (Box 3).
 1
 1
 1*
 1*
 1*
 1*
Multiple sclerosis
a. Without prolonged immobility
 1
 1
 1
 2
 1
 1
b. With prolonged immobility
 1
 1
 1
 2
 1
 3
Depressive Disorders
Depressive disorders
1*
 1*
 1*
 1*
 1*
 1*
Reproductive Tract Infections and Disorders
Vaginal bleeding patterns
Initiation
 Continuation
 —
a. Irregular pattern without heavy bleeding
 1
 1
 1
 2
 2
 2
 1
b. Heavy or prolonged bleeding (includes regular and irregular patterns)
 2*
 1*
 2*
 2*
 2*
 2*
 1*
Unexplained vaginal bleeding
(suspicious for serious condition) before evaluation
 Initiation
 Continuation
 Initiation
 Continuation
 —
4*
 2*
 4*
 2*
 3*
 3*
 2*
 2*
Endometriosis
2
 1
 1
 1
 1
 1
Benign ovarian tumors (including cysts)
 1
 1
 1
 1
 1
 1
Severe dysmenorrhea
2
 1
 1
 1
 1
 1
Gestational trophoblastic disease
This condition is associated with increased risk for
adverse health events as a result of pregnancy (Box 3).
a. Suspected gestational trophoblastic disease
(immediate postevacuation)
  i. Uterine size first trimester
 1*
 1*
 1*
 1*
 1*
 1*
  ii. Uterine size second trimester
 2*
 2*
 1*
 1*
 1*
 1*
b. Confirmed gestational trophoblastic disease (after initial evacuation and during monitoring)
 Initiation
 Continuation
 Initiation
 Continuation
 —
  i. Undetectable or nonpregnant β-hCG levels
 1*
 1*
 1*
 1*
 1*
 1*
 1*
 1*
  ii. Decreasing β-hCG levels
 2*
 1*
 2*
 1*
 1*
 1*
 1*
 1*
  iii. Persistently elevated β-hCG levels or malignant disease, with no evidence or suspicion of intrauterine disease
 2*
 1*
 2*
 1*
 1*
 1*
 1*
 1*
  iv. Persistently elevated β-hCG levels or malignant disease, with evidence or suspicion of intrauterine disease
 4*
 2*
 4*
 2*
 1*
 1*
 1*
 1*
Cervical ectropion
1
 1
 1
 1
 1
 1
Cervical intraepithelial neoplasia
1
 2
 2
 2
 1
 2
Cervical cancer (awaiting treatment)
 Initiation
 Continuation
 Initiation
 Continuation
 —
4
 2
 4
 2
 2
 2
 1
 2
Breast disease
Breast cancer is associated with increased risk for
adverse health events as a result of pregnancy (Box 3).
a. Undiagnosed mass
 1
 2*
 2*
 2*
 2*
 2*
b. Benign breast disease
 1
 1
 1
 1
 1
 1
c. Family history of cancer
 1
 1
 1
 1
 1
 1
d. Breast cancer
  i. Current
 1
 4
 4
 4
 4
 4
  ii. Past and no evidence of current disease for 5 years
 1
 3
 3
 3
 3
 3
Endometrial hyperplasia
1
 1
 1
 1
 1
 1
Endometrial cancer
This condition is associated with increased risk for adverse health events as a result of pregnancy (Box 3).
 Initiation
 Continuation
 Initiation
 Continuation
 —
4
 2
 4
 2
 1
 1
 1
 1
Ovarian cancer
This condition is associated with increased risk for adverse health events as a result of pregnancy (Box 3).
 1
 1
 1
 1
 1
 1
Uterine fibroids
2
 2
 1
 1
 1
 1
Anatomical abnormalities
a. Distorted uterine cavity (any congenital or acquired uterine abnormality distorting the uterine cavity in a manner that is incompatible with IUD placement)
 4
 4
 —
b. Other abnormalities (including cervical stenosis or cervical lacerations) not distorting the uterine cavity or interfering with IUD placement
 2
 2
Pelvic inflammatory disease
Initiation
 Continuation
 Initiation
 Continuation
 —
a. Current PID
 4
 2*
 4
 2*
 1
 1
 1
 1
b. Past PID
  i. With subsequent pregnancy
 1
 1
 1
 1
 1
 1
 1
 1
  ii. Without subsequent pregnancy
 2
 2
 2
 2
 1
 1
 1
 1
Sexually transmitted infections
Initiation
 Continuation
 Initiation
 Continuation
 —
a. Current purulent cervicitis or chlamydial infection or gonococcal infection
 4
 2*
 4
 2*
 1
 1
 1
 1
b. Vaginitis (including Trichomonas vaginalis and bacterial vaginosis)
 2
 2
 2
 2
 1
 1
 1
 1
c. Other factors related to STIs
 2*
 2
 2*
 2
 1
 1
 1
 1
HIV
High risk for HIV infection
Initiation
 Continuation
 Initiation
 Continuation
 —
1*
 1*
 1*
 1*
 1
 1
 1
 1
HIV infection
For persons with HIV infection who are not clinically well or not receiving ARV therapy, this condition is associated with increased risk for adverse health events as a result of pregnancy (Box 3).
 —
 —
 —
 —
 1*
 1*
 1*
 1*
a. Clinically well receiving ARV therapy
 1
 1
 1
 1
 —
 —
 —
 —
b. Not clinically well or not receiving ARV therapy
 2
 1
 2
 1
 —
 —
 —
 —
Other Infections
Schistosomiasis
Schistosomiasis with fibrosis of the liver is associated 
with increased risk for adverse health events
as a result of pregnancy (Box 3).
a. Uncomplicated
 1
 1
 1
 1
 1
 1
b. Fibrosis of the liver (if severe, see recommendations for Cirrhosis)
 1
 1
 1
 1
 1
 1
Tuberculosis
This condition is associated with increased risk for adverse health events as a result of pregnancy (Box 3).
 Initiation
 Continuation
 Initiation
 Continuation
 —
a. Nonpelvic
 1
 1
 1
 1
 1*
 1*
 1*
 1*
b. Pelvic
 4
 3
 4
 3
 1*
 1*
 1*
 1*
Malaria
1
 1
 1
 1
 1
 1
Endocrine Conditions
Diabetes
Insulin-dependent diabetes; diabetes with nephropathy,
retinopathy, or neuropathy; diabetes with other vascular
disease; or diabetes of >20 years’ duration are associated
with increased risk for adverse health events
as a result of pregnancy (Box 3).
a. History of gestational disease
 1
 1
 1
 1
 1
 1
b. Nonvascular disease
  i. Non-insulin dependent
 1
 2
 2
 2
 2
 2
  ii. Insulin dependent
 1
 2
 2
 2
 2
 2
c. Nephropathy, retinopathy, or neuropathy
 1
 2
 2
 3
 2
 3/4*
d. Other vascular disease or diabetes of >20 years’ duration
 1
 2
 2
 3
 2
 3/4*
Thyroid disorders
a. Simple goiter
 1
 1
 1
 1
 1
 1
b. Hyperthyroid
 1
 1
 1
 1
 1
 1
c. Hypothyroid
 1
 1
 1
 1
 1
 1
Gastrointestinal Conditions
Inflammatory bowel disease (ulcerative colitis or Crohn’s disease)
 1
 1
 1
 2
 2
 2/3*
Gallbladder disease
a. Asymptomatic
 1
 2
 2
 2
 2
 2
b. Symptomatic
  i. Current
 1
 2
 2
 2
 2
 3
  ii. Treated by cholecystectomy
 1
 2
 2
 2
 2
 2
  iii. Medically treated
 1
 2
 2
 2
 2
 3
History of cholestasis
a. Pregnancy related
 1
 1
 1
 1
 1
 2
b. Past COC related
 1
 2
 2
 2
 2
 3
Viral hepatitis
Initiation
 Continuation
a. Acute or flare
 1
 1
 1
 1
 1
 3/4*
 2
b. Chronic
 1
 1
 1
 1
 1
 1
 1
Cirrhosis
Decompensated cirrhosis is associated with increased
risk for adverse health events as a result of
pregnancy (Box 3).
a. Compensated (normal liver function)
 1
 1
 1
 1
 1
 1
b. Decompensated (impaired liver function)
 1
 2
 2
 3
 2
 4
Liver tumors
Hepatocellular adenoma and malignant liver tumors are
associated with increased risk for adverse health events
as a result of pregnancy (Box 3).
a. Benign
  i. Focal nodular hyperplasia
 1
 2
 2
 2
 2
 2
  ii. Hepatocellular adenoma
 1
 2
 2
 3
 2
 4
b. Malignant (hepatocellular carcinoma)
 1
 3
 3
 3
 3
 4
Respiratory Conditions
Cystic fibrosis
This condition is associated with increased risk for adverse health events as a result of pregnancy (Box 3).
 1*
 1*
 1*
 2*
 1*
 1*
Hematologic Conditions
Thalassemia
2
 1
 1
 1
 1
 1
Sickle cell disease
This condition is associated with increased risk for adverse health events as a result of pregnancy (Box 3).
 2
 1
 1
 2/3*
 1
 4
Iron-deficiency anemia
2
 1
 1
 1
 1
 1
Solid Organ Transplantation
Solid organ transplantation
This condition is associated with increased risk for adverse health events as a result of pregnancy (Box 3).
 Initiation
 Continuation
 Initiation
 Continuation
 —
a. No graft failure
 1
 1
 1
 1
 2
 2/3*
 2
 2*
b. Graft failure
 2
 1
 2
 1
 2
 2/3*
 2
 4
Drug Interactions
Antiretrovirals used for prevention (PrEP)
or treatment of HIV infection
See the following guidelines for the most up-to-date recommendations on drug-drug interactions between hormonal contraception and antiretrovirals: 1) Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United (https://clinicalinfo.hiv.gov/en/guidelines/perinatal/prepregnancy-counseling-childbearing-age-overview?view=full#table-3) (4) and 2) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-overview?view=full) (5).
a. Nucleoside reverse transcriptase inhibitors (NRTIs)
 Initiation
 Continuation
 Initiation
 Continuation
 —
  i. Abacavir (ABC)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
  ii. Tenofovir (TDF)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
  iii. Zidovudine (AZT)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
  iv. Lamivudine (3TC)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
  v. Didanosine (DDI)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
  vi. Emtricitabine (FTC)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
  vii. Stavudine (D4T)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
b. Nonnucleoside reverse transcriptase inhibitors (NNRTIs)
  i. Efavirenz (EFV)
 1/2*
 1*
 1/2*
 1*
 2*
 1*
 2*
 2*
  ii. Etravirine (ETR)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
  iii. Nevirapine (NVP)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
  iv. Rilpivirine (RPV)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
c. Ritonavir-boosted protease inhibitors
  i. Ritonavir-boosted atazanavir (ATV/r)
 1/2*
 1*
 1/2*
 1*
 2*
 1*
 2*
 2*
  ii. Ritonavir-boosted darunavir (DRV/r)
 1/2*
 1*
 1/2*
 1*
 2*
 1*
 2*
 2*
  iii. Ritonavir-boosted fosamprenavir (FPV/r)
 1/2*
 1*
 1/2*
 1*
 2*
 1*
 2*
 2*
  iv. Ritonavir-boosted lopinavir (LPV/r)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
  v. Ritonavir-boosted saquinavir (SQV/r)
 1/2*
 1*
 1/2*
 1*
 2*
 1*
 2*
 2*
  vi. Ritonavir-boosted tipranavir (TPV/r)
 1/2*
 1*
 1/2*
 1*
 2*
 1*
 2*
 2*
d. Protease inhibitors without ritonavir
  i. Atazanavir (ATV)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 2*
  ii. Fosamprenavir (FPV)
 1/2*
 1*
 1/2*
 1*
 2*
 2*
 2*
 3*
  iii. Indinavir (IDV)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
  iv. Nelfinavir (NFV)
 1/2*
 1*
 1/2*
 1*
 2*
 1*
 2*
 2*
e. CCR5 co-receptor antagonists
  i. Maraviroc (MVC)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
f. HIV integrase strand transfer inhibitors
  i. Raltegravir (RAL)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
  ii. Dolutegravir (DTG)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
  iii. Elvitegravir (EVG)
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
g. Fusion inhibitors
  i. Enfuvirtide
 1/2*
 1*
 1/2*
 1*
 1
 1
 1
 1
Anticonvulsant therapy
a. Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, and oxcarbazepine)
 1
 1
 2*
 1*
 3*
 3*
b. Lamotrigine
 1
 1
 1
 1
 1
 3*
Antimicrobial therapy
a. Broad-spectrum antibiotics
 1
 1
 1
 1
 1
 1
b. Antifungals
 1
 1
 1
 1
 1
 1
c. Antiparasitics
 1
 1
 1
 1
 1
 1
d. Rifampin or rifabutin therapy
 1
 1
 2*
 1*
 3*
 3*
Psychotropic medications
a. Selective serotonin reuptake inhibitors (SSRIs)
 1
 1
 1
 1
 1
 1
St. John’s wort 1
 1
 2
 1
 2
 2

Abbreviations: ARV = antiretroviral; BMI = body mass index; CHC = combined hormonal contraceptive; COC = combined oral contraceptive; Cu-IUD = copper intrauterine device; DMPA = depot medroxyprogesterone acetate; DRSP = drospirenone; DVT = deep venous thrombosis; hCG = human chorionic gonadotropin; HDL = high-density lipoprotein; IUD = intrauterine device; LDL = low-density lipoprotein; LNG-IUD = levonorgestrel intrauterine device; NA = not applicable; PE = pulmonary embolism; PID = pelvic inflammatory disease; POP = progestin-only pill; PrEP = pre-exposure prophylaxis; STI = sexually transmitted infection; VTE = venous thromboembolism.

* Consult the appendix for this contraceptive method for a clarification to this classification.